Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
We observed an association of higher Ki-67 (show MKI67 Antibodies) expression with Gleason sum National Comprehensive Cancer Network risk (P=0.013) and PSA (show PLAG1 Antibodies) recurrence
Results show that urinary PSA (show PLAG1 Antibodies) glycoforms are able to discriminate prostate cancer from protastatic hyperplasia with higher sensitivity and specificity for prostate cancer than those of the serum PSA (show PLAG1 Antibodies) marker.
results suggest that overexpression of CRISP-3 (show CRISP3 Antibodies) in prostate tumor may maintain higher PSA (show PLAG1 Antibodies) expression and lower ANXA1 (show ANXA1 Antibodies) expression
No significant differences in in KLK3 (show KLKB1 Antibodies) expression were found between radical prostatectomy-prostate cancer and radical prostatectomy-benign samples.
BMI should be taken into consideration when referring men to a prostate biopsy based on serum PSA (show PLAG1 Antibodies)-levels.
Ad5 (show PSEN2 Antibodies)/35E1aPSESE4 is effective in marking PSA (show PLAG1 Antibodies)/PSMA (show FOLH1 Antibodies)-positive prostate cancer cells in patient blood to improve the efficacy of utilizing CTCs as a biomarker.
The synthesis and serum levels of PSA (show PLAG1 Antibodies) are directly affected by prostate tumor cell miR (show MLXIP Antibodies)-183.
Prostate cancer gene 3 gene expression discriminates LN metastasis and might outperform prostate specific antigen gene activity in reflecting tumor cell burden in pelvic LNs of PCa (show FLVCR1 Antibodies) patients.
detection of prostate cancer and according to PSA (show PLAG1 Antibodies) screening to distinguish men with prostate cancer from men with benign prostatic hyperplasia.
Of those patients who took AA with food at PSA (show PLAG1 Antibodies) progression, a PSA (show PLAG1 Antibodies) decline was observed in 3 of the 19 (16%) men, including 3 of the 14 men who had an initial response to AA (21%).
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its protein product is a protease present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. Serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms.
, prostate specific antigen
, prostate-specific antigen
, plasma kallikrein B1
, kallikrein-related peptidase 3